The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
MJFF Research Grant, 2008Evaluation of Gastrointestinal Motility in Parkinsonian Rodents
Objective/Rationale:
Gastrointestinal (GI) symptoms, such as nausea, bloating, and constipation occur in nearly every patient afflicted with Parkinson’s Disease (PD) at some point in their illness... -
MJFF Research Grant, 2008Are Anti-Parkinsonian Treatments Disease Modifying?
Objective/Rationale:
Current treatments of Parkinson’s disease are not thought to slow the progression of the disease but just appear to result in temporary relief of symptoms. There is some evidence... -
MJFF Research Grant, 2008QE3 Trial Ancillary Biomarkers Study
Objective/Rationale:
The QE3 trial is a large multicenter clinical trial designed to determine whether the nutritional supplement coenzyme Q10, which traps a potentially dangerous type of chemical in... -
Target Validation, 2006Identification of therapeutics that protect against toxins and genes implicated in Parkinson’s disease via the Forkhead-mediated transcription pathway
Loss of dopaminergic neurons is one of the cardinal features of Parkinson’s disease. Medications that can delay or prevent dopaminergic loss could be beneficial in treating PD, but the optimal...
-
Target Validation, 2007Targeting Urate: A Molecular Correlate of Both Risk and Progression in PD
Objective/Rationale:
Urate (a natural antioxidant, caffeine analog and DNA metabolite) is the first molecule linked to both the risk of typical Parkinson’s disease and its rate of progression. Higher... -
Rapid Response Innovation Awards, 2007Potential Utility of Novel CNS-active Experimental Therapeutics for Parkinson's Disease
Objective/Rationale:
Evidence suggests that overproduction of inflammatory molecules, called proinflammatory cytokines, from glial cells in the brain can contribute to nerve cell death and accelerate...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.